All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether sarilumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes clinical improvement D28b compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes clinical improvement D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether clazakizumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes clinical improvement D60 or moref compared with standard care/placebo (very low certainty).
1 finding from 1 review
Adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes clinical improvement D28b compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D60 or more ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
1 finding from 1 review
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether siltuximab changes clinical improvement D28b compared with standard care/placebo (very low certainty).
1 finding from 1 review
WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19
Tociliuzumab showed no clear difference in WHO progression score (level 7 or above) D28 compared with standard care/placebo (low certainty).
1 finding from 1 review